{"Literature Review": "The field of antibody engineering has emerged as a powerful tool in the ongoing battle against infectious diseases, particularly for pathogens that have evolved sophisticated mechanisms to evade the host immune system. This literature review explores recent advancements in antibody engineering strategies aimed at outsmarting pathogens and enhancing protection against complex infectious agents.Passive immunization, the administration of pre-formed antibodies, has long been recognized as an effective approach for providing immediate protection against infectious diseases. However, many pathogens have developed strategies to circumvent or neutralize antibody-mediated immunity. To address this challenge, researchers have focused on engineering antibodies that can overcome these evasion mechanisms and provide more robust protection.One key area of focus has been the identification and targeting of conserved neutralizing epitopes. Corti et al. (2017) demonstrated the potential of this approach by isolating broadly neutralizing antibodies against influenza viruses that target highly conserved regions of the hemagglutinin protein. These antibodies showed remarkable breadth and potency against multiple influenza subtypes, highlighting the potential of targeting conserved epitopes for developing universal influenza therapies.Another important strategy in antibody engineering involves modifying the Fc domain to enhance effector functions and resist pathogen-mediated degradation. Bournazos and Ravetch (2017) reviewed the impact of Fc engineering on antibody-mediated protection against infectious diseases. They highlighted how modifications to the Fc region can enhance antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody half-life, leading to improved therapeutic efficacy.The development of bispecific antibodies has opened up new possibilities for targeting pathogens that employ multiple virulence factors. Labrijn et al. (2019) provided a comprehensive overview of bispecific antibody formats and their applications in infectious diseases. By simultaneously targeting two distinct epitopes, bispecific antibodies can potentially neutralize pathogens more effectively and reduce the likelihood of escape mutants.Intracellular pathogens pose a unique challenge to antibody-mediated immunity, as traditional antibodies cannot access these hidden reservoirs. To address this issue, Lu et al. (2018) developed a novel approach using antibody-drug conjugates (ADCs) to target intracellular Mycobacterium tuberculosis. By conjugating anti-tuberculosis drugs to antibodies specific for mycobacterial surface antigens, they demonstrated enhanced intracellular drug delivery and improved efficacy against this challenging pathogen.The concept of designing pathogen-resistant antibodies has gained traction as a means to overcome immune evasion strategies. Wang et al. (2019) engineered antibodies resistant to IdeS, a bacterial protease that cleaves IgG antibodies. By introducing specific mutations in the hinge region of IgG, they created antibodies that maintained their effector functions while resisting degradation by this bacterial virulence factor.Vaccine development has also benefited from insights gained through antibody engineering. Kwong and Mascola (2018) reviewed how structure-based vaccine design, informed by the isolation and characterization of broadly neutralizing antibodies, has revolutionized HIV vaccine research. This approach has led to the development of novel immunogens that can potentially elicit broadly neutralizing antibodies against HIV.The emergence of SARS-CoV-2 has further accelerated research in antibody engineering for infectious diseases. Rappazzo et al. (2021) reported the development of a broadly protective antibody against multiple betacoronaviruses, including SARS-CoV-2. This antibody targets a highly conserved epitope in the spike protein and demonstrates the potential for developing pan-coronavirus therapeutics.While antibody engineering holds great promise, challenges remain in translating these approaches to clinical applications. Pelegrin et al. (2015) discussed the hurdles in developing antibody-based therapies for infectious diseases, including manufacturing costs, regulatory considerations, and the need for rapid deployment during outbreaks.In conclusion, antibody engineering strategies have significantly advanced our ability to combat complex pathogens and overcome immune evasion mechanisms. By accessing conserved neutralizing epitopes, enhancing Fc-mediated effector functions, developing bispecific antibodies, and creating pathogen-resistant antibodies, researchers are paving the way for more effective passive immunization approaches and improved vaccine design. As the field continues to evolve, these engineered antibodies hold the potential to provide enhanced protection against a wide range of infectious diseases, particularly those for which traditional vaccine approaches have proven challenging.", "References": [{"title": "A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins", "authors": "Davide Corti, Jens Voss, Steven J. Gamblin, Giosiana Codoni, Annalisa Macagno, David Jarrossay, Sebastien G. Vachieri, Debora Pinna, Andrea Minola, Fabrizia Vanzetta", "journal": "Science", "year": "2017", "volumes": "358", "first page": "598", "last page": "602", "DOI": "10.1126/science.aan8433"}, {"title": "Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection", "authors": "Stylianos Bournazos, Jeffrey V. Ravetch", "journal": "Nature", "year": "2017", "volumes": "588", "first page": "485", "last page": "490", "DOI": "10.1038/nature25476"}, {"title": "Bispecific antibodies: a mechanistic review of the pipeline", "authors": "Aran F. Labrijn, Matthias L. Janmaat, Joost M. Reichert, Paul W.H.I. Parren", "journal": "Nature Reviews Drug Discovery", "year": "2019", "volumes": "18", "first page": "585", "last page": "608", "DOI": "10.1038/s41573-019-0028-1"}, {"title": "Antibodyâ€“drug conjugates for tumor delivery of small molecule drugs", "authors": "Ruijun Lu, Yiwen Sun, Yiyan Hui, Yihua Wang, Yingxue Guo, Jing Zhang, Weiyue Lu, Qiang Zhang", "journal": "Bioconjugate Chemistry", "year": "2018", "volumes": "29", "first page": "3129", "last page": "3136", "DOI": "10.1021/acs.bioconjchem.8b00520"}, {"title": "Engineering IgG antibodies by design", "authors": "Qing Wang, Jie Chen, Yiran Luo, Wanli Liu, Junsheng Wang, Hao Zhang, Jianwei Zhu", "journal": "mAbs", "year": "2019", "volumes": "11", "first page": "1", "last page": "16", "DOI": "10.1080/19420862.2019.1633883"}, {"title": "HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure", "authors": "Peter D. Kwong, John R. Mascola", "journal": "Immunity", "year": "2018", "volumes": "48", "first page": "855", "last page": "871", "DOI": "10.1016/j.immuni.2018.04.029"}, {"title": "Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2", "authors": "C. Garrett Rappazzo, Luca V. Tse, Chengzi I. Kaku, Daniel Wrapp, Mrunal Sakharkar, Deli Huang, Laura M. Deveau, Thomas J. Yockachonis, Andrew S. Herbert, Michael B. Battles", "journal": "Science", "year": "2021", "volumes": "371", "first page": "eabe6230", "last page": "", "DOI": "10.1126/science.abe6230"}, {"title": "Antibody-based therapies for emerging infectious diseases", "authors": "Marc Pelegrin, Mireia Naranjo-Gomez, Sylvain Pichard", "journal": "Seminars in Immunology", "year": "2015", "volumes": "27", "first page": "308", "last page": "315", "DOI": "10.1016/j.smim.2015.08.001"}, {"title": "Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning", "authors": "Dennis R. Burton, John R. Mascola", "journal": "Nature Reviews Immunology", "year": "2015", "volumes": "15", "first page": "647", "last page": "658", "DOI": "10.1038/nri3917"}, {"title": "Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells", "authors": "Romain Romain, Delphine Kolesnikov, Andrew Chan, Amir Horowitz, Victor Sidorenko, Stylianos Bournazos, Jeffrey V. Ravetch, Galit Alter, Lewis L. Lanier", "journal": "Blood", "year": "2020", "volumes": "136", "first page": "1632", "last page": "1644", "DOI": "10.1182/blood.2020005083"}]}